Table 1.

Characteristics of the study population

Study arm
DFMO + aspirin (N = 52)Double placebo (N = 52)Total (N = 104)P
Age0.7424a
 N
 Mean (SD)62.8 (9.43)62.3 (8.83)62.6 (9.09)
 Median63.062.062.5
 Range46.0–83.050.0–79.046.0–83.0
Sex, n (%)0.1678b
 Female27 (51.9%)20 (38.5%)47 (45.2%)
 Male25 (48.1%)32 (61.5%)57 (54.8%)
Race, n (%)0.3607b
 White50 (96.2%)52 (100.0%)102 (98.1%)
 African American1 (1.9%)0 (0.0%)1 (1.0%)
 Other1 (1.9%)0 (0.0%)1 (1.0%)
Prior aspirin use, n (%)0.8356b
 Yes18 (34.6%)17 (32.7%)35 (33.7%)
 No34 (65.4%)35 (67.3%)69 (66.3%)
Prior cancer, n (%)1.0000b
 Yes1 (1.9%)1 (1.9%)2 (1.9%)
 No51 (98.1%)51 (98.1%)102 (98.1%)
Prior advanced adenomas, n (%)0.3150b
 Yes52 (100.0%)51 (98.1%)103 (99.0%)
 No0 (0.0%)1 (1.9%)1 (1.0%)
BMI0.0682a
 Mean (SD)31.3 (7.66)28.7 (5.67)30.0 (6.83)
 Median30.327.428.3
 Range19.4–54.220.6–52.919.4–54.2
  • aWilcoxon rank-sum P value.

  • bχ2 P value. Missing data: DFMO + aspirin (n = 2), Double placebo (n = 1).